Generate Biomedicines, a trailblazer in the realm of generative biology, has successfully raised an impressive $273 million in its latest funding round, reinforcing its commitment to revolutionizing the landscape of therapeutics. The company is at the forefront of pioneering innovative approaches that leverage advanced biological design and computational methods to create breakthrough therapeutics aimed at treating a range of complex diseases. This significant capital infusion will not only enable Generate Biomedicines to accelerate its research and development initiatives but also expand its portfolio of novel therapies that can address unmet medical needs. With the funds, the company plans to further enhance its state-of-the-art platform which integrates artificial intelligence with biological insights, paving the way for streamlined and efficient drug discovery. Additionally, the funding will support ongoing clinical trials and expand collaborations with leading research institutions and pharmaceutical partners. Generate Biomedicines is poised to make substantial strides in bringing new and effective treatment options to patients worldwide, and with this latest financial boost, the company is well-equipped to advance its mission of transforming therapeutic possibilities through generative biology. As the healthcare landscape continues to evolve, Generate Biomedicines remains dedicated to harnessing the power of biology to illuminate new pathways for therapeutic innovation.
Biomedicines Secures $273 Million in Series C Funding to Advance Groundbreaking Therapeutics in Generative Biology
Recently funded · $273.0M Series cBiotechnology
Get the full Generate Biomedicines company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
